Clinical trials: Prostate Cancer Patients
Prostatic Neoplasms
Study of ORIC-101 in Combination With Enzalutamide
The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with enzalutamide (Xtandi®) when…
- Trial name
- NCT04033328
- Testing
- ORIC-101, enzalutamide 40 MG oral capsule [Xtandi]
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- ORIC Pharmaceuticals
High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR)…
- Trial name
- NCT07875881
- Testing
- Deutenzalutamide Soft Capsules + ADT
- Where
- 3 sites in China
- Volunteers
- 1,044 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostate Cancer
Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
The intention of this study is to investigate how many patients with prostate cancer, planned to be treated with LHRH analogues without history of surgery or radiotherapy, are suffering from LUTS.
- Trial name
- ANALUTS (NCT02542501)
- Where
- 32 sites in Portugal, Spain
- Volunteers
- 470 people
- Sponsor
- Ipsen
Cancer, Prostate Cancer
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT02325557
- Testing
- ADXS31-142, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Advaxis, Inc.
Prostate Cancer
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Primary Objectives: To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with oral daily abiraterone acetate and prednisone in…
- Trial name
- NCT01511536
- Testing
- Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Sanofi
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic…
- Trial name
- NCT01193244
- Testing
- Orteronel, Prednisone
- Where
- 240 sites in United States, Australia and 38 more
- Volunteers
- 1,560 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
mCRPC
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
- Trial name
- NCT04145375
- Testing
- ZEN003694, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Zenith Epigenetics
Prostate Cancer
PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy
The purpose of this study is to develop and validate a blood-based diagnostic test that will predict prostate biopsy outcome as positive or negative for prostate cancer.
- Trial name
- PReCISE (NCT00966095)
- Where
- 17 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Source MDx
Prostate Cancer, Pharmacokinetics of Enzalutamide
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A multiple dose relative bioavailability study in patients with prostate cancer comparing a capsule and a tablet formulation of enzalutamide.
- Trial name
- NCT01902251
- Testing
- Enzalutamide tablet, Enzalutamide capsule
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Astellas Pharma Europe B.V.
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Prostate Cancer
Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy
The aim of this clinical trial is to evaluate the efficacy and safety of the WST09-mediated vascular-targeted photodynamic therapy (VTP) in patients with localized prostate cancer recurrent after external radiation therapy or…
- Trial name
- NCT00312442
- Testing
- Treatment with WST09 Vascular Photodynamic therapy
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- STEBA France
Prostatic Neoplasms
PK in Pts With HRPC & Skeletal Metastes
Primary objective: To investigate the biodistribution, radiation dosimetry, and pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body weight [b.w.] [=110 kBq/kg based on the 2015 National…
- Trial name
- NCT00667537
- Testing
- Radium-223 chloride (Xofigo®, BAY88-8223) injection
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Bayer
Prostate Cancer
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients
- Trial name
- NCT00245466
- Testing
- Degarelix
- Volunteers
- 88 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.
The purpose of the protocol, is to assess the feasibility of conducting a larger trial to evaluate the effect of a psychological intervention on the well-being of patients on luteinizing hormone-releasing hormone (LHRH) analogs…
- Trial name
- EXPEDIENT (NCT01562522)
- Testing
- Psychological counseling
- Where
- 3 sites in Netherlands
- Volunteers
- 6 people
- Sponsor
- Ipsen
Prostatic Neoplasms
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT02217566
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 4 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Janssen Research & Development, LLC
Non-Metastatic Prostate Cancer
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were…
- Trial name
- Capri (NCT00673205)
- Testing
- Bicalutamide
- Where
- 128 sites in Australia, Austria and 14 more
- Volunteers
- 3,588 people
- Sponsor
- AstraZeneca
Prostate Cancer
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.
- Trial name
- NCT00801242
- Testing
- Degarelix 240 mg / 80 mg
- Where
- 52 sites in Belgium, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms
EPO906 Therapy in Patients With Prostate Cancer
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause prostate cancer.
- Trial name
- NCT00035113
- Testing
- epothilone b
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device
The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting clinically significant prostate cancer in a standard clinical environment.
- Trial name
- NCT02524860
- Testing
- Focal-Fusion Bx
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Focal Healthcare Inc.
Prostate Neoplasms
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system…
- Trial name
- NCT00474383
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Cougar Biotechnology, Inc.